EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Utility of metastasis-directed radiotherapy with and without hormonal therapy in management of oligometastatic prostate cancer

William S Chen iD, Abuzar Moradi Tuchayi, Ali Sabbagh iD, Inkyu Kim iD, Evan Porter iD, Amir Ashraf-Ganjouei, Yun Rose Li iD, Alon Witztum, Abhejit Rajagopal, Steven N Seyedin iD, Roxanna Juarez iD, Peter R Carroll iD und 4 weitere

JNCI Cancer Spectrum · 2025

DOI: 10.1093/jncics/pkaf096 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JNCI Cancer Spectrum, 2025. Verfasst von William S Chen und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, University of California, San Francisco, San Francisco, CA, United States. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Androgen Antagonists, Radiotherapy, Image-Guided. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: ASTRO-PCF Career Development Award to End Prostate Cancer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Metastasis-directed radiotherapy (MDT) is the mainstay in management of oligometastatic prostate cancer (PCa), and PSMA-PET is currently the most sensitive imaging modality for localizing PCa metastases. The efficacy of MDT guided by PSMA-PET imaging with and without androgen deprivation therapy (ADT) ± androgen-receptor pathway inhibitor (ARPI) has not yet been well characterized. We sought to evaluate the efficacy of PSMA PET-guided MDT.

Methods

This is a single-institutional retrospective study of patients diagnosed with metastatic PCa by PSMA-PET imaging who were treated with MDT. Survival analyses were performed using the Kaplan-Meier method with Cox proportional hazards testing for significance. Cumulative incidence analyses were performed with Gray’s testing for significance.

Results

One hundred and ninety-four metastatic lesions from 101 patients identified by PSMA PET were irradiated with MDT. Forty-seven of the 79 (59%) patients with hormone-sensitive PCa (HSPC) received ADT ± ARPI along with MDT. Four of 194 lesions (2.1%) demonstrated radiographic progression after MDT, with a median follow-up of 22.4 months. Two-year cumulative incidence of progression from HSPC to CRPC was 11% in patients who received ADT ± ARPI and 35% in those who did not (P = .027). Median biochemical progression free survival of patients with CRPC, HSPC treated without ADT or ARPI, and HSPC treated with ADT ± ARPI was 5.4, 7.6, and 43.9 months, respectively (P < .0001). No Grade 3-5 adverse effects were observed.

Conclusions

MDT guided by PSMA-PET imaging is well-tolerated and delays biochemical progression in patients with CRPC and HSPC, with a greater effect observed in patients also receiving ADT ± ARPI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsAndrogen AntagonistsRadiotherapy, Image-GuidedHumansMaleRetrospective StudiesAgedMiddle AgedPositron-Emission TomographyAged, 80 and overNeoplasm MetastasisKaplan-Meier EstimateProstate-Specific AntigenGlutamate Carboxypeptidase IIProportional Hazards Models

Substanzen

Androgen AntagonistsProstate-Specific AntigenGlutamate Carboxypeptidase II

Autor:innen und Institutionen

  • Department of Radiation Oncology, University of California, San Francisco, San Francisco, CA, United States.
  • Department of Urology, University of California, San Francisco, San Francisco, CA, United States.
  • Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, United States.
  • Department of Radiation Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, United States.
  • Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, San Francisco, CA, United States.
  • Bakar Computational Health Sciences Institute, University of California, San Francisco, San Francisco, CA, United States.

ORCID-Profile: William S Chen, Ali Sabbagh, Inkyu Kim, Evan Porter, Yun Rose Li, Steven N Seyedin, Roxanna Juarez, Peter R Carroll, Felix Y Feng, Thomas A Hope, Julian C Hong

Förderung

  • ASTRO-PCF Career Development Award to End Prostate Cancer

Zitieren

APA

Chen, W. S., Tuchayi, A. M., Sabbagh, A., Kim, I., Porter, E., Ashraf-Ganjouei, A., Li, Y. R., Witztum, A., Rajagopal, A., Seyedin, S. N., Juarez, R., Carroll, P. R., Feng, F. Y., Small, E. J., Hope, T. A., & Hong, J. C. (2025). Utility of metastasis-directed radiotherapy with and without hormonal therapy in management of oligometastatic prostate cancer. JNCI Cancer Spectrum. https://doi.org/10.1093/jncics/pkaf096

Vancouver

Chen WS, Tuchayi AM, Sabbagh A, Kim I, Porter E, Ashraf-Ganjouei A, et al. Utility of metastasis-directed radiotherapy with and without hormonal therapy in management of oligometastatic prostate cancer. JNCI Cancer Spectrum. 2025. doi:10.1093/jncics/pkaf096

BibTeX
@article{Chen2025,
  author = {Chen, William S and Tuchayi, Abuzar Moradi and Sabbagh, Ali and Kim, Inkyu and Porter, Evan and Ashraf-Ganjouei, Amir and Li, Yun Rose and Witztum, Alon and Rajagopal, Abhejit and Seyedin, Steven N and Juarez, Roxanna and Carroll, Peter R and Feng, Felix Y and Small, Eric J and Hope, Thomas A and Hong, Julian C},
  title = {Utility of metastasis-directed radiotherapy with and without hormonal therapy in management of oligometastatic prostate cancer},
  journal = {JNCI Cancer Spectrum},
  year = {2025},
  doi = {10.1093/jncics/pkaf096}
}
Kostenlos starten →